NeOnc Q3 net loss narrowed to $4.4 million from $8.6 million a year earlier
NeOnc reported third-quarter 2026 results, with its net loss falling to $4.4 million from $8.6 million in the year-earlier quarter and total operating expenses declining to $5.8 million from $6.9 million. Cash and cash equivalents rose to $6.2 million at September 30, 2026, helped by a September registered direct offering of approximately $15 million gross, and the company said it will present NEO100 and NEO212 data on November 13, 2026.
Key points
- Net loss attributable to common stockholders was $7.3 million, or $(0.28) per share, versus $8.6 million, or $(0.45) per share, in Q3 2025; the figure includes $2.8 million of noncash deemed dividends.
- Cash and cash equivalents were approximately $6.2 million at September 30, 2026, up from approximately $2.0 million at June 30, 2026.
- R&D expenses were $1.3 million, compared with $0.7 million in Q3 2025, while G&A expenses fell to $0.6 million from $0.9 million.
- Data from NEO100 and NEO212 will be presented in two posters on November 13, 2026, at the Society for Neuro-Oncology Annual Meeting in Philadelphia.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.